Fenwarth, L.; Fournier, E.; Cheok, M.; Boyer, T.; Gonzales, F.; Castaigne, S.; Boissel, N.; Lambert, J.; Dombret, H.; Preudhomme, C.;
et al. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. Int. J. Mol. Sci. 2020, 21, 5626.
https://doi.org/10.3390/ijms21165626
AMA Style
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C,
et al. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences. 2020; 21(16):5626.
https://doi.org/10.3390/ijms21165626
Chicago/Turabian Style
Fenwarth, Laurène, Elise Fournier, Meyling Cheok, Thomas Boyer, Fanny Gonzales, Sylvie Castaigne, Nicolas Boissel, Juliette Lambert, Hervé Dombret, Claude Preudhomme,
and et al. 2020. "Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment" International Journal of Molecular Sciences 21, no. 16: 5626.
https://doi.org/10.3390/ijms21165626
APA Style
Fenwarth, L., Fournier, E., Cheok, M., Boyer, T., Gonzales, F., Castaigne, S., Boissel, N., Lambert, J., Dombret, H., Preudhomme, C., & Duployez, N.
(2020). Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. International Journal of Molecular Sciences, 21(16), 5626.
https://doi.org/10.3390/ijms21165626
